Insulin Glargine Market Size
| Study Period | 2018 - 2029 |
| Market Size (2024) | USD 1.54 Billion |
| Market Size (2029) | USD 2.09 Billion |
| CAGR (2024 - 2029) | 6.28 % |
| Fastest Growing Market | North America |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Insulin Glargine Market Analysis
The Insulin Glargine Market size is estimated at USD 1.54 billion in 2024, and is expected to reach USD 2.09 billion by 2029, growing at a CAGR of 6.28% during the forecast period (2024-2029).
The COVID-19 pandemic has resulted in a surge in diabetic complexities, which is driving the insulin demand in the market. Type 1 diabetes can be characterized as insulin-requiring, while Type 2 diabetes can be characterized as insulin-dependent diabetes. People with diabetes have a 300% increased risk of being hospitalized compared to those without diabetes, and, thus, they incur more healthcare expenses than non-diabetic people. Patients with Type 2 diabetes require many corrections throughout the day to maintain nominal blood glucose levels, such as the administration of additional insulin or ingestion of additional carbohydrates. Achieving nominal results can be very difficult without multiple daily injections of insulin or insulin pump therapy. This is driving the demand for insulin on a global scale, which is expected to drive the market studied during the forecast period.
Insulin Glargine Market Trends
Insulin Glargine Market Access has Widened
Sanofi released Toujeo in the European region as the basal insulin for the treatment of type-1 and type-2 diabetes mellitus in adults. According to Sanofi data, Toujeo reported net sales of EUR 933 million globally in 2020, driven primarily by strong performances in European nations. In January 2020, Sanofi announced that the European Commission (EC) had expanded the current indication for Toujeo (insulin glargine 300 units/mL) to include children and adolescents with diabetes. Toujeo is now indicated for the treatment of diabetes mellitus in adults, adolescents, and children under the age of 6 years. This is driving the market in the forecast period, whereas Basaglar was the first biosimilar to Lantus to be launched in some European countries. It offers the core protein sequence of Lantus to patients. It is expected to observe an exponential increase in sales volumes during the forecast period, primarily due to its growing adoption and lower cost than its competitors in the European region.
With approximately 56% of the market share, the United States has the biggest global sales of Humalog. The majority of diabetic medicine producers view the nation as a crucial market for boosting overall worldwide sales. For the treatment of diabetes, Humalog is marketed in the US under many brand names, including Humalog Mix 75/25, Humalog U-100, Humalog U-200, and Humalog Mix 50/50. All type-1 diabetics, as well as a tiny proportion of type-2 diabetics, require daily insulin injections as part of their treatment. According to the ADA, government insurance (including Medicare, Medicaid, and the military) pays for 67.3% of the cost of diabetes care in the US. Private insurance (30.7%) and uninsured people (2%), respectively, fund the remaining amount.
North America to Grow with the Highest CAGR over the Forecast Period
Despite advancements in medical technology and health systems, patients in this region are not coping with the challenges of chronic diseases. The incidence of these diseases increased significantly over the past few years. In North America, the market share of traditional human insulin is higher due to its affordability. Novolin holds the highest market share of more than 80%, followed by Humulin and Insuman. However, these traditional brands are facing fierce competition from the local drug market. Among the drugs in the long-acting insulin segment, Lantus holds the highest market share of more than 39.6%, followed by Levemir. New-generation insulin glargine, like Toujeo, Tresiba, and Basaglar, are available in only a few countries. These drugs witnessed good market penetration in the countries they were launched.
Due to the high incidence of diabetes in the region brought on by a sedentary lifestyle, North America, and specifically the United States, now hold a monopoly on the worldwide human insulin market. In the United States, where nearly 50% of the earnings for the makers of insulin come from within the nation, the cost aspect is the main worry. The majority of long-acting insulin, Lantus, sold worldwide is in the United States. The majority of diabetic medicine producers view the nation as a crucial market for boosting overall worldwide sales. Lantus has a disproportionately large market share in the US and is the most often used basal insulin globally. Because it is economically accessible to patients, the conventional North American human insulin pharmaceuticals market is anticipated to expand throughout the projected period. The market share leader is Humulin, followed by Novolin. The conventional North American human insulin medication market in the United States has no generic rivals.
Insulin Glargine Industry Overview
The global insulin glargine market is moderately consolidated, mainly consisting of three major manufacturers (Sanofi, Novo Nordisk, and Eli Lilly) with a global market presence. The remaining manufacturers are confined to the other local or region-specific manufacturers. Mergers and acquisitions that happened between the players in the recent past helped the companies strengthen their market presence. Eli Lilly and Boehringer Ingelheim have an alliance in developing and commercializing Basaglar (insulin glargine), whereas Biocon collaborated with Mylan to develop Semglee (an insulin glargine biosimilar). Prominent players, such as Sanofi, Novo Nordisk, and Lilly, have created a monopoly in the market through their established supply chains and branding, which has resulted in substantial market penetration. These companies work in tandem with several administrative and health agencies to deploy competitive strategies and restrict or eliminate competition from emerging market players.
Insulin Glargine Market Leaders
-
Sanofi Aventis
-
Novo Nordisk AS
-
Biocon
-
Eli Lilly and Company
-
Julphar
*Disclaimer: Major Players sorted in no particular order
Insulin Glargine Market News
- October 2022: Novo Nordisk announced headline results from the ONWARDS 5 phase 3a trial with once-weekly insulin icodec in people with type-2 diabetes. The ONWARDS 5 trial was a 52-week, open-label efficacy and safety treat-to-target trial investigating once-weekly insulin versus once-daily basal insulin (insulin degludec or insulin glargine U100/U300).
- March 2022: Biocon acquired Viatris Biosimilars for USD 3.3 billion. Biocon has been acquired in two different US states. The company's most targeted sectors include life science (50%) and medical products (50%).
Insulin Glargine Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
- 4.2 Market Drivers
- 4.3 Market Restraints
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Bargaining Power of Suppliers
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Threat of New Entrants
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
-
5.1 Insulin Glargine
- 5.1.1 Lantus
- 5.1.2 Basaglar
- 5.1.3 Toujeo
- 5.1.4 Soliqua/Suliqua
- 5.1.5 Insulin Glargine Biosimilars
-
5.2 Geography
- 5.2.1 North America
- 5.2.1.1 United States
- 5.2.1.2 Canada
- 5.2.1.3 Rest of North America
- 5.2.2 Europe
- 5.2.2.1 France
- 5.2.2.2 Germany
- 5.2.2.3 Italy
- 5.2.2.4 Spain
- 5.2.2.5 United Kingdom
- 5.2.2.6 Russia
- 5.2.2.7 Rest of Europe
- 5.2.3 Latin America
- 5.2.3.1 Mexico
- 5.2.3.2 Brazil
- 5.2.3.3 Rest of Latin America
- 5.2.4 Asia-Pacific
- 5.2.4.1 Japan
- 5.2.4.2 South Korea
- 5.2.4.3 China
- 5.2.4.4 India
- 5.2.4.5 Australia
- 5.2.4.6 Vietnam
- 5.2.4.7 Malaysia
- 5.2.4.8 Indonesia
- 5.2.4.9 Philippines
- 5.2.4.10 Thailand
- 5.2.4.11 Rest of Asia-Pacific
- 5.2.5 Middle East and Africa
- 5.2.5.1 Saudi Arabia
- 5.2.5.2 Iran
- 5.2.5.3 Egypt
- 5.2.5.4 Oman
- 5.2.5.5 South Africa
- 5.2.5.6 Rest of Middle East and Africa
6. MARKET INDICATORS
- 6.1 Type-1 Diabetes Population
- 6.2 Type-2 Diabetes Population
7. COMPETITIVE LANDSCAPE
-
7.1 Company Profiles
- 7.1.1 Novo Nordisk AS
- 7.1.2 Sanofi Aventis
- 7.1.3 Eli Lilly and Company
- 7.1.4 Biocon
- 7.1.5 Julphar
- *List Not Exhaustive
- 7.2 Company Share Analysis
8. MARKET OPPORTUNITIES AND FUTURE TRENDS
Insulin Glargine Industry Segmentation
Insulin glargine is a long-acting type of insulin used to treat type 1 and type 2 diabetes mellitus in both adults and children. It provides a steady level of insulin in the body for 24 hours and helps control blood sugar levels. The global insulin glargine market is segmented by type (Lantus, Basaglar, Toujeo, Soliqua/Suliqua, Insulin Glargine Biosimilars) and geography (North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa). The report offers the value (in USD million) and volume (in million mL) for the above segments. This report will provide a segment-wise breakdown (value and volume) for all the countries covered under the table of contents.
| Insulin Glargine | Lantus | |
| Basaglar | ||
| Toujeo | ||
| Soliqua/Suliqua | ||
| Insulin Glargine Biosimilars | ||
| Geography | North America | United States |
| Canada | ||
| Rest of North America | ||
| Geography | Europe | France |
| Germany | ||
| Italy | ||
| Spain | ||
| United Kingdom | ||
| Russia | ||
| Rest of Europe | ||
| Geography | Latin America | Mexico |
| Brazil | ||
| Rest of Latin America | ||
| Geography | Asia-Pacific | Japan |
| South Korea | ||
| China | ||
| India | ||
| Australia | ||
| Vietnam | ||
| Malaysia | ||
| Indonesia | ||
| Philippines | ||
| Thailand | ||
| Rest of Asia-Pacific | ||
| Geography | Middle East and Africa | Saudi Arabia |
| Iran | ||
| Egypt | ||
| Oman | ||
| South Africa | ||
| Rest of Middle East and Africa |
Insulin Glargine Market Research FAQs
How big is the Insulin Glargine Market?
The Insulin Glargine Market size is expected to reach USD 1.54 billion in 2024 and grow at a CAGR of 6.28% to reach USD 2.09 billion by 2029.
What is the current Insulin Glargine Market size?
In 2024, the Insulin Glargine Market size is expected to reach USD 1.54 billion.
Who are the key players in Insulin Glargine Market?
Sanofi Aventis, Novo Nordisk AS, Biocon, Eli Lilly and Company and Julphar are the major companies operating in the Insulin Glargine Market.
Which is the fastest growing region in Insulin Glargine Market?
North America is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Insulin Glargine Market?
In 2024, the North America accounts for the largest market share in Insulin Glargine Market.
What years does this Insulin Glargine Market cover, and what was the market size in 2023?
In 2023, the Insulin Glargine Market size was estimated at USD 1.45 billion. The report covers the Insulin Glargine Market historical market size for years: 2018, 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Insulin Glargine Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Insulin Glargine Industry Report
Statistics for the 2024 Insulin Glargine market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Insulin Glargine analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
